-
1 Comment
Cordlife Group Limited is currently in a long term uptrend where the price is trading 7.0% above its 200 day moving average.
From a valuation standpoint, the stock is 79.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Cordlife Group Limited's total revenue rose by 208.9% to $51M since the same quarter in the previous year.
Its net income has increased by 77.0% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 172.3% to $4M since the same quarter in the previous year.
Based on the above factors, Cordlife Group Limited gets an overall score of 5/5.
Exchange | SG |
---|---|
CurrencyCode | SGD |
ISIN | SG2E64980112 |
Sector | Healthcare |
Industry | Diagnostics & Research |
Target Price | 1.41 |
---|---|
Beta | 0.58 |
Market Cap | 39M |
PE Ratio | None |
Dividend Yield | None |
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, gut microbiome banking, and lifestyle genetic screening services for adults. In addition, it offers Moms Up, a mobile application that offers parenting resources, as well as sprouts for health, wellness, and lifestyle needs. Further, the company provides medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for P8A.SG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025